New standard of care for Limited-Stage Small-Cell Lung Cancer, summary by Estela Rodriguez
Estela Rodriguez shared a post on X:
“Out today in ADRIATIC New England Journal of Medicine one of the most impactful American Society of Clinical Oncology – Lung presentations this year:
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
New standard of care
- N=760 Durvalumab x2 yrs post CRT
- mOS: 56 vs 33mos (HR 0.74)
- mPFS: 16.6 vs 9.2 mos (HR 0.76).”
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Authors: Ying Cheng, David R. Spigel, Byoung Chul Cho, Konstantin K. Laktionov, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabe, Eva Lotte Buchmeier, John Wen-Cheng Chang, Yoshimasa Shiraishi, Sema Sezgin Goksu, Andrzej Badzio, Anhui Shi, Davey B. Daniel, Nguyen Thi Thai Hoa, Milada Zemanova, Helen Mann, Hema Gowda, Haiyi Jiang and Suresh Senan.
Source: Estela Rodriguez/X
Dr. Estelamari (Estela) Rodriguez is an Associate Director of Community Outreach and Co-Lead Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is a board certified in medical oncology and hematology. In the past, she was the Medical Director Thoracic Oncology at Mount Sinai Medical Center Miami Beach. Dr. Rodriguez has a special interest in the early detection of lung cancer and increasing access to clinical trials. She is a community leader and mentor to many women and minorities in medicine. Her passion is community engagement and empowering women to be advocates for their health and profession.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023